Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Lixia Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-2859-4687; OpenAlex author ID A5103279685. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 4 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 9

  1. PPP3CB inhibits pancreatic cancer progression by promoting ATOH8 translocation and transcriptionally regulating Sp1. First author DOI 10.1016/j.lfs.2025.123631↗
  2. The role of phosphoprotein phosphatases catalytic subunit genes in pancreatic cancer. Last author DOI 10.1042/bsr20203282↗
  3. Development and validation of a radiomics nomogram to discriminate advanced pancreatic cancer with liver metastases or other metastatic patterns. Last author DOI 10.3233/cbm-210190↗
  4. Role of CT texture features for predicting outcome of pancreatic cancer patients with liver metastases. Last author DOI 10.7150/jca.49569↗
  5. Clinical significance of site-specific metastases in pancreatic cancer: a study based on both clinical trial and real-world data. Co-author DOI 10.7150/jca.50317↗
  6. The clinical implication of CD45RA+ naïve T cells and CD45RO+ memory T cells in advanced pancreatic cancer: a proxy for tumor biology and outcome prediction. Co-author DOI 10.1002/cam4.1988↗
  7. A Systematic Inflammation-based Model in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.30561↗
  8. Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and rea… First author DOI 10.1002/cam4.1573↗
  9. Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer. Co-author DOI 10.1038/s41598-017-00288-4↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junjie Hang · 8 shared papers, 2018–2025 · strength 1.08
  2. Kequn Xu · 5 shared papers, 2018–2021 · strength 0.54
  3. Siyuan Zhou · 3 shared papers, 2019–2021 · strength 0.38
  4. Hua Jiang · 3 shared papers, 2018–2019 · strength 0.26
  5. Xu Che · 1 shared paper, 2025 · strength 0.24
  6. Tao Liu · 1 shared paper, 2025 · strength 0.24
  7. Xuguang Yang · 2 shared papers, 2019 · strength 0.18
  8. Hanyu Zhou · 2 shared papers, 2019 · strength 0.18
  9. Tianliang Zhang · 1 shared paper, 2021 · strength 0.16
  10. Tiening Zhang · 1 shared paper, 2021 · strength 0.14
  11. Benny Chung-Ying Zee · 1 shared paper, 2021 · strength 0.14
  12. Junjie Huang · 1 shared paper, 2019 · strength 0.09
  13. Yuli Lin · 1 shared paper, 2019 · strength 0.09
  14. Meng Zhuo · 1 shared paper, 2017 · strength 0.07
  15. Ting Han · 1 shared paper, 2017 · strength 0.07
  16. Feng Jiao · 1 shared paper, 2017 · strength 0.07
  17. Hai Xia Hu · 1 shared paper, 2017 · strength 0.07
  18. Lei Wang · 1 shared paper, 2017 · strength 0.07
  19. Liwei Wang · 1 shared paper, 2017 · strength 0.07
  20. Leilei Wu · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.